Citigroup Cuts argenx (ARGX) Price Target to $1,232
Key Points
- Citigroup reduced its price target for argenx SE from $1,301 to $1,232, keeping its Buy rating intact.
- Citigroup's $1,232 price target implies 41.08% upside from argenx SE's ($ARGX) current $873.25 share price.
- As of October 27, 2026, argenx shares were recently trading around $873.25, below both the target mean price of $1,150.35 and the previous target.
- Analysts generally remain positive, with firms like Morgan Stanley and Wells Fargo maintaining their Overweight and Buy ratings, respectively.
Get argenx SE text alerts
We text you when insiders, Congress, analysts or big funds move on $ARGX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures
On October 27, 2026, Citigroup lowered its price target on argenx SE (ARGX) to $1,232 from $1,301, while keeping its Buy rating. This change was noted in Citigroup's research note on the same day.
Citigroup’s new target reflects a shift in expectations for the company's stock, which is currently priced significantly lower than the target. The recent share price of argenx is $873.25, which is about 24.1% below the mean analyst price target of $1,150.35.
ARGX
argenx SE
Citigroup vs. the S&P 500
Hypothetical returns from Citigroup's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in argenx SE
Several other institutional investors have also been active with argenx SE. Jupiter Topco LLC holds 2,474,015 shares, with a value of about $2.18 billion after increasing its position by 1,237,008 shares. Artisan Partners Limited Partnership owns 1,508,778 shares, having added 40,810 shares recently, worth approximately $1.33 billion. Avoro Capital Advisors LLC has maintained its stake at 1,000,000 shares, valued at $882.5 million, while RTW Investments LP continues to hold 709,446 shares worth about $626.1 million.
argenx SE Stock Up 0.5%
As of October 27, 2026, argenx SE shares closed at $882.48. The stock is currently trading below its 50-day moving average of $953.35 by about 8.4%. It is also below its 52-week high of $1,072.75 by approximately 18.6%, but above its 52-week low of $661.85 by 31.9%.
$ARGX price target
argenx SE daily closes and this analyst's $1,232 target. Not advice.
Recent Earnings
In its most recent earnings report, argenx SE reported a trailing twelve-month revenue of approximately $5.92 billion and an EPS of $28.87. The company has shown a net margin of 31.7%. The next earnings report is expected on February 25, 2027.
Analysts Set New Price Targets
On October 23, 2026, multiple firms maintained their ratings on argenx SE. Morgan Stanley kept an Overweight rating with a target of $1,190, while Guggenheim maintained a Buy rating with a target of $1,120. Wells Fargo also kept an Overweight rating but with a lower target of $1,336. Evercore ISI Group maintained an Outperform rating with a target of $1,090. Citigroup's new target of $1,232 fits within this context of generally favorable analyst opinions.
About argenx SE
argenx SE is a biopharmaceutical company based in Amsterdam, Netherlands. It focuses on developing therapies for autoimmune diseases. The company has products like VYVGART, which treats conditions such as generalized Myasthenia Gravis and immune thrombocytopenia. This recent price target adjustment by Citigroup reflects the ongoing evaluation of its growth prospects in a competitive healthcare market.
Bottom Line
Investors should keep an eye on argenx SE as it approaches its next earnings date on February 25, 2027. Citigroup's decision to lower the price target highlights the cautious outlook among analysts, although many still maintain positive ratings. As the company continues to develop its product offerings, further updates from analysts will be key to watch.
Related Filing Alerts
Source: Citigroup's rating change on $ARGX (Oct 27, 2026). Written by software, not financial advice. How we make alerts